 |
Werner Höllriegl
VP, Head of In Vivo Gene Therapy | Evotec
Werner Höllriegl is heading In Vivo Gene Therapy at Evotec GT in Orth an der Donau, Austria. He received his degree in Veterinary Medicine from the University of Veterinary Medicine Vienna, Austria. After spending a couple of years as Assistant Professor at the Department of Anesthesiology, he moved into industrial research spending more than 15 years in different Pharma Companies (Baxter, AstraZeneca, Novartis Institutes for BioMedical Research, Baxalta, Shire, Takeda) in Research and Nonclinical Development, focussing on biologics and in vivo gene therapy.
|
 |
Hanspeter Rottensteiner
VP, Head of In Vitro Gene Therapy | Evotec
Hanspeter Rottensteiner is heading In Vitro Gene Therapy at Evotec GT in Austria. Biochemist by training, Hanspeter has more than 10 years in academia, and 15 years of experience in Pharma (Baxter, Takeda) in senior positions. He brings significant expertise in drug development of biologics and gene therapies, with a strong focus on rare diseases. He received his degree in Biochemistry from the University of Vienna, Austria.
|
 |
Rüdiger Fritsch
Principle Scientist, Metabolic Disease | Evotec
Rüdiger Fritsch is heading a transcriptomics team at Evotec. He has recieved his PhD from the Max Planck Institute for Biophysical Chemistry. With over 15 years of experience as a biologist, Rüdiger has a strong expertise in omics.
|